MX2020007828A - Anticuerpo, fragmento funcional o sonda del mismo contra antigenos tumorales. - Google Patents
Anticuerpo, fragmento funcional o sonda del mismo contra antigenos tumorales.Info
- Publication number
- MX2020007828A MX2020007828A MX2020007828A MX2020007828A MX2020007828A MX 2020007828 A MX2020007828 A MX 2020007828A MX 2020007828 A MX2020007828 A MX 2020007828A MX 2020007828 A MX2020007828 A MX 2020007828A MX 2020007828 A MX2020007828 A MX 2020007828A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- probe
- amino acid
- acid sequence
- functional fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Abstract
La presente invención proporciona un anticuerpo o fragmentos de anticuerpos funcionales, o sonda del mismo dirigido contra un grupo único de antígenos identificados en el cáncer. La presente invención comprende secuencias nucleotídicas derivadas del anticuerpo monoclonal L2A5. El anticuerpo o fragmento de anticuerpo funcional, o sonda del mismo incluye un dominio de cadena pesada variable y un dominio de cadena ligera variable que tiene una secuencia de aminoácidos proporcionada en la presente descripción. Esta conjugación de secuencia de ADN/secuencia de aminoácidos es única y nunca había sido descrita anteriormente. La presente invención proporciona además un anticuerpo o un fragmento de anticuerpo funcional o un conjugado o una proteína recombinante útil en la detección, tratamiento y prevención de enfermedades humanas, incluido el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT110526A PT110526B (pt) | 2018-01-26 | 2018-01-26 | Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais |
PCT/PT2019/000001 WO2019147152A1 (en) | 2018-01-26 | 2019-01-17 | L2a5 antibody or functional fragment thereof against tumour antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007828A true MX2020007828A (es) | 2020-11-24 |
Family
ID=65244573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007828A MX2020007828A (es) | 2018-01-26 | 2019-01-17 | Anticuerpo, fragmento funcional o sonda del mismo contra antigenos tumorales. |
Country Status (15)
Country | Link |
---|---|
US (1) | US11353460B2 (es) |
EP (1) | EP3743726A1 (es) |
JP (1) | JP7324777B2 (es) |
KR (1) | KR20210005546A (es) |
CN (1) | CN113287018A (es) |
AU (1) | AU2019211035A1 (es) |
BR (1) | BR112020014931A2 (es) |
CA (1) | CA3089300A1 (es) |
EA (1) | EA202091760A1 (es) |
IL (1) | IL276208A (es) |
MX (1) | MX2020007828A (es) |
PT (1) | PT110526B (es) |
SG (1) | SG11202006897VA (es) |
WO (1) | WO2019147152A1 (es) |
ZA (1) | ZA202005023B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2619976A (en) * | 2022-06-24 | 2023-12-27 | Cellmabs S A | Humanised antibodies or functional fragments thereof against tumour antigens |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
CA1340587C (en) * | 1988-03-11 | 1999-06-08 | Thomas J. Kjeldsen | Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates |
WO1995029927A2 (en) | 1994-05-02 | 1995-11-09 | Biomira, Inc. | Process for preparation of glycosides of tumor-associated carbohydrate antigens |
CA2286798C (en) | 1997-04-16 | 2014-01-07 | Sloan-Kettering Institute For Cancer Research | Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof |
JP3809277B2 (ja) | 1998-03-05 | 2006-08-16 | 生化学工業株式会社 | N−アセチルグルコサミン−6−o−硫酸基転移酵素のポリペプチド及びそれをコードするdna |
GB9917012D0 (en) | 1999-07-20 | 1999-09-22 | Pharmacia & Upjohn Spa | Combined preparations comprising antitumor agents |
WO2005010485A2 (en) | 2003-07-15 | 2005-02-03 | The Regents Of The University Of California | Methods for detecting and analyzing n-glycolylneuraminic acid (neu5gc) in biological materials |
US8148335B2 (en) | 2004-06-23 | 2012-04-03 | Children's Hospital & Research Center Oakland | De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy |
JP2010505775A (ja) | 2006-10-04 | 2010-02-25 | クーベンハヴンス・ユニヴェルシテット | Muc1に対する癌特異的な免疫反応の産生及び癌特異的muc1抗体 |
JP5156887B2 (ja) | 2007-02-14 | 2013-03-06 | 独立行政法人科学技術振興機構 | 2−6シアリル6−スルホ糖鎖に対する抗体 |
EP2014302A1 (en) | 2007-07-12 | 2009-01-14 | Institut Curie | An antibody specific for the Tn antigen for the treatment of cancer |
FI20070853A0 (fi) | 2007-11-09 | 2007-11-09 | Glykos Finland Oy | Glykaania sitovat monoklonaaliset vasta-aineet |
EP2287202A1 (en) | 2009-08-07 | 2011-02-23 | Dublin City University | Anti-sialic acid antibody molecules |
WO2011088385A2 (en) | 2010-01-15 | 2011-07-21 | The Regents Of The University Of California | Compositions and methods for detecting cancer |
WO2014178196A1 (ja) | 2013-05-02 | 2014-11-06 | 独立行政法人産業技術総合研究所 | シアリル化糖鎖を認識するモノクローナル抗体 |
DK3004337T3 (da) | 2013-05-29 | 2017-11-13 | Cellectis | Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system |
CA2922478C (en) | 2013-08-26 | 2020-09-29 | MabVax Therapeutics, Inc. | Nucleic acids encoding human antibodies to sialyl-lewisa |
EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
US20180280504A1 (en) | 2014-10-10 | 2018-10-04 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
AU2016315704B2 (en) * | 2015-08-31 | 2022-08-11 | Helixmith Co., Ltd | Anti-sialyl Tn chimeric antigen receptors |
EP3645703A1 (en) * | 2017-05-25 | 2020-05-06 | Instituto de Patologia e Imunologia da Universidad do Porto (IPATIMUP) | Detection and isolation of cancer cells from body fluids based on a glycosylation pattern and methods of use thereof |
-
2018
- 2018-01-26 PT PT110526A patent/PT110526B/pt active IP Right Grant
-
2019
- 2019-01-17 WO PCT/PT2019/000001 patent/WO2019147152A1/en unknown
- 2019-01-17 KR KR1020207024660A patent/KR20210005546A/ko active Search and Examination
- 2019-01-17 EA EA202091760A patent/EA202091760A1/ru unknown
- 2019-01-17 SG SG11202006897VA patent/SG11202006897VA/en unknown
- 2019-01-17 JP JP2020560859A patent/JP7324777B2/ja active Active
- 2019-01-17 CA CA3089300A patent/CA3089300A1/en active Pending
- 2019-01-17 AU AU2019211035A patent/AU2019211035A1/en active Pending
- 2019-01-17 CN CN201980022395.6A patent/CN113287018A/zh active Pending
- 2019-01-17 BR BR112020014931-4A patent/BR112020014931A2/pt unknown
- 2019-01-17 MX MX2020007828A patent/MX2020007828A/es unknown
- 2019-01-17 US US16/964,900 patent/US11353460B2/en active Active
- 2019-01-17 EP EP19702492.0A patent/EP3743726A1/en active Pending
-
2020
- 2020-07-22 IL IL276208A patent/IL276208A/en unknown
- 2020-08-13 ZA ZA2020/05023A patent/ZA202005023B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113287018A (zh) | 2021-08-20 |
ZA202005023B (en) | 2022-01-26 |
PT110526A (pt) | 2019-07-26 |
CA3089300A1 (en) | 2019-08-01 |
US11353460B2 (en) | 2022-06-07 |
KR20210005546A (ko) | 2021-01-14 |
IL276208A (en) | 2020-09-30 |
PT110526B (pt) | 2021-02-04 |
WO2019147152A1 (en) | 2019-08-01 |
BR112020014931A2 (pt) | 2020-12-08 |
EA202091760A1 (ru) | 2020-11-23 |
EP3743726A1 (en) | 2020-12-02 |
JP2021516254A (ja) | 2021-07-01 |
SG11202006897VA (en) | 2020-08-28 |
JP7324777B2 (ja) | 2023-08-10 |
AU2019211035A1 (en) | 2020-08-06 |
US20210033616A1 (en) | 2021-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20071055A1 (es) | Anticuerpos anti mn | |
CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
CY1121471T1 (el) | Δεσμευομενες πρωτεϊνες, που περιλαμβανουν αντισωματα, παραγωγα αντισωματων και θραυσματα αντισωματων που δεσμευονται ειδικα me cd154 και χρησεις αυτων | |
CY1124435T1 (el) | Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α | |
CY1122270T1 (el) | Αντι-παραγοντα xi μονοκλωνικα αντισωματα και μεθοδοι χρησης αυτων | |
EA202092933A1 (ru) | Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии | |
PH12019501773A1 (en) | Anti-ccr7 antibody drug conjugates | |
EA201791706A1 (ru) | Связывающие icos белки | |
WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
PE20050712A1 (es) | Anticuerpos rg1 | |
CY1115927T1 (el) | Αντισωματα εναντιον της κολοβωμενης παραλλαγης ctf-611 του her2 | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
AU2018449846A8 (en) | An anti-B7-H3 antibody | |
SG10201806025TA (en) | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen | |
EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
WO2019066435A3 (ko) | Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물 | |
EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
WO2020257789A3 (en) | Anti-tim-3 antibodies | |
NZ764878A (en) | Human monoclonal antibodies to ganglioside gd2 | |
MX2021011040A (es) | Anticuerpos dirigidos contra c5ar. | |
CR20210324A (es) | Anticuerpos anti-pmel 17 y conjugados de los mismos | |
MX2020007828A (es) | Anticuerpo, fragmento funcional o sonda del mismo contra antigenos tumorales. | |
AU2018345715A8 (en) | DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer | |
NZ750451A (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 |